Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Thursday 10 June, 2021

Ergomed plc

Result of AGM

RNS Number : 4856B
Ergomed plc
10 June 2021
 

 

 

PRESS RELEASE

 

 

 

Results of 2021 Annual General Meeting and Board Appointment

Guildford, UK - 10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today were passed by way of a poll. 

The full text of the resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com .

Further to the Company's announcement on 10 May 2021, Mark Enyedy was appointed to the Company's Board of Directors as a Non-Executive Director with effect from closing of the AGM.

 

ENDS

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray

 

 




About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:  http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGVBLBFFQLEBBZ

a d v e r t i s e m e n t